A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H. Kerridge, Helen Weston, Phoebe Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer

Research output: Contribution to journal › Meeting Abstract › peer-review

1 Meeting Abstract

1 results

2021

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)
Mollee, P., Reynolds, J., Janowski, W., Quach, H., Campbell, P., Gibbs, S. D., Lee, S., D'Rozario, J., Taylor, K., Cochrane, T., Wallington-Beddoe, C. T., Kwok, F., Weber, N., Kerridge, I. H., Weston, H., Ho, P. J., Horvath, N., Yuen, F. & Spencer, A., 23 Nov 2021, In: Blood. 138, S1, p. 2728-2729 2 p.
Research output: Contribution to journal › Meeting Abstract › peer-review

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Research output

Search results

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)